The Journal of Practical Medicine ›› 2022, Vol. 38 ›› Issue (19): 2495-2500.doi: 10.3969/j.issn.1006⁃5725.2022.19.023

• Reviews • Previous Articles     Next Articles

Research progress of denosumab in the treatment of osteoporosis in hemodialysis patients

LI ShishiLIU Fanna.   

  1. Department of Nephrologythe First Affiliated Hospital of Ji′nan UniversityGuangzhou 510000China

  • Online:2022-10-10 Published:2022-10-10
  • Contact: LIU Fanna E⁃mail:13560421216@126.com

Abstract:

Osteoporosis is a disease where low bone mineral density and microstructure deterioration lead to low bone strength and high risk of fracture. Because metabolic disorders will accelerate bone loss and renal failurewhich can increase the risk of osteoporosis that will lead to fracture or even death. Denosumab is a receptor activator of nuclear factor⁃κB ligand inhibitor that is widely used in the treatment of osteoporosis. In recent yearsthere are increasing applications of denosumab in hemodialysis patients with osteoporosis. This paper reviews the application and research progress of denosumab in the treatment of osteoporosis in hemodialysis patients

Key words:

osteoporosis, hemodialysis, denosumab